Novo Nordisk shares in Denmark fall by up to 7% despite new targets — CNBC
In Denmark, shares of pharmaceutical company Novo Nordisk fell by up to 7% in early trading in Copenhagen on September 21, 2026. This came after the company unveiled new growth targets in the obesity treatment drug market.
Plans through 2035
As CNBC reports, Novo Nordisk plans to bring more than five drugs with the potential to become multi-blockbusters to market by 2030. The company seeks to convince investors that it can compete in an increasingly crowded market, of which it was one of the pioneers.
More current news is available on the UA.News Telegram channel Telegram.
By 2035, the manufacturer expects to generate more than 150 billion Danish kroner, or about $23 billion, in sales from its drug development portfolio.
Revenue expectations
Novo Nordisk also expects its revenue growth rate in 2026–2030 to match that of other companies in the industry. The announced targets were intended to demonstrate to investors the company’s ability to compete in the obesity drug segment.
